Study results currently support the simultaneous use of three antiretroviral agents including two nucleoside reverse transcriptase inhibitors and a protease inhibitor for the treatment of human immunodeficiency (HIV) infection. Such regimens have been recommended by the USA panel of the International AIDS Society for all patients considering treatment, and similar recommendations are being proposed by other organisations as well. This paper reviews the currently recommended triple therapy regimens, as well as novel triple therapy regimens using didanosine (2',3'-dideoxyinosine; ddI] plus stavudine (2',3'-didehydro-2',3'- dideoxythymidine; d4T).
|Original language||English (US)|
|Number of pages||5|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas